Fennec Pharmaceuticals Inc. FENC
NASDAQ · United States · Health Technology
$10.20-0.13 (-1.26%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~ ~ 84% of Patients Had Grade 0 Hearing Loss by Brock Criteria; No Grade 3 or Grade 4 Hearing Loss Was Observed ~ ~ Objective Responses Observed in 23 of 24 Evaluable Patients (95.8%); Prospective Pharmacokinetic Analyses Provide New Mechanistic Insight Supporting the Six-Hour PEDMARK® Administration Interva
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Fennec Pharmaceuticals is back in focus after analysts lifted their fair value estimate from US$15.33 to US$17.67 per share, pointing to a higher assessed equity value for the stock. Recent commentary links this change to stronger than expected PEDMARK revenue, broader use across several tumor types, and updated views on operating leverage that are feeding into refreshed models. As you read on, you will see how this evolving narrative could shape the way you track Fennec Pharmaceuticals from...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.